31 drug patent registrations by the MFDS, half of them are AstraZeneca

[Newsmp] In August, the number of drug patents registered by the Ministry of Food and Drug Safety (MFDS) exceeded 30.

According to the MFDS information platform (https://nedrug.mfds.go.kr/), the number of patent registrations, which fell from 39 in May to 10 in June, increased to 29 in July, and rose to 31 in August.

Certain products accounted for nearly half of the monthly patent registrations. AstraZeneca’s anemia treatment Evrenzo has registered 15 patents, three cases for five doses each.

Following Evrenzo, migraine treatment Reyvow (Ildong Pharmaceutical) was registered with four patents, and Teva-Handok’s Huntington’s Disease medication Austedo with three.

The MFDS put two patents for LG Chem’s combination drug Zemidapa (DPP-4 inhibitors + SGLT-2 inhibitors), Lilly Korea’s RET target drug Retevmo, and Bayer’s Kerendia, a medicine used to treat chronic kidney disease in adults with type 2 diabetes, on the list of patented medicines.

Moreover, Bayer registered Vitrakvi, a medicine for solid tumors that are caused by certain abnormal NTRK genes, SK Chemicals Teglutik, treatment for patients with amyotrophic lateral sclerosis (ALS), and Elyson Pharm Nebirosta, a beta-blocker and statin combination.

Among them, Bayer listed two medicines, Kerendia and Vitrakvi, and was the only company to register multiple items on the patented medicines list.